Impetigo: A need for new therapies in a world of increasing antimicrobial resistance

Nathan Martin D'CUNHA, Gregory Peterson, Kavya Baby, Jackson THOMAS

Research output: Contribution to journalComment/debate

6 Citations (Scopus)

Abstract

What is known and objective: Impetigo is a highly contagious bacterial skin infection and is one of the most common skin infections in children. Antibiotics are the first-line treatment when multiple lesions exist, but with an increasing prevalence of antibiotic-resistant bacteria the successful management of impetigo in the future is an area of concern.
Comment: Current treatment options that favour the use of oral antibiotic therapy are increasingly problematic. Widespread use of these agents contributes to antimicrobial resistance and has adverse consequences for individuals and communities. There is a need for new topical antimicrobials and antiseptics as an alternative treatment strategy.
What is new and conclusion: To successfully treat impetigo into the future and ensure that therapy does not contribute to bacterial resistance, additional research is required to ascertain the usefulness of alternative agents, including new topical antimicrobials and antiseptics.
Original languageEnglish
Pages (from-to)150-153
Number of pages4
JournalJournal of Clinical Pharmacy and Therapeutics
Volume43
Issue number1
DOIs
Publication statusPublished - Feb 2018

Fingerprint

Impetigo
Local Anti-Infective Agents
Anti-Bacterial Agents
Therapeutics
Skin
Bacterial Infections
Bacteria
Infection
Research

Cite this

D'CUNHA, Nathan Martin ; Peterson, Gregory ; Baby, Kavya ; THOMAS, Jackson. / Impetigo: A need for new therapies in a world of increasing antimicrobial resistance. In: Journal of Clinical Pharmacy and Therapeutics. 2018 ; Vol. 43, No. 1. pp. 150-153.
@article{14bbfbfd9d244b81aba29cf04415657b,
title = "Impetigo: A need for new therapies in a world of increasing antimicrobial resistance",
abstract = "What is known and objective: Impetigo is a highly contagious bacterial skin infection and is one of the most common skin infections in children. Antibiotics are the first-line treatment when multiple lesions exist, but with an increasing prevalence of antibiotic-resistant bacteria the successful management of impetigo in the future is an area of concern.Comment: Current treatment options that favour the use of oral antibiotic therapy are increasingly problematic. Widespread use of these agents contributes to antimicrobial resistance and has adverse consequences for individuals and communities. There is a need for new topical antimicrobials and antiseptics as an alternative treatment strategy.What is new and conclusion: To successfully treat impetigo into the future and ensure that therapy does not contribute to bacterial resistance, additional research is required to ascertain the usefulness of alternative agents, including new topical antimicrobials and antiseptics.",
keywords = "antibiotics, antimicrobials, bacterial resistance, efficacy, fusidic acid, impetigo, mupirocin",
author = "D'CUNHA, {Nathan Martin} and Gregory Peterson and Kavya Baby and Jackson THOMAS",
year = "2018",
month = "2",
doi = "10.1111/jcpt.12639",
language = "English",
volume = "43",
pages = "150--153",
journal = "Journal of Clinical and Hospital Pharmacy",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "1",

}

Impetigo: A need for new therapies in a world of increasing antimicrobial resistance. / D'CUNHA, Nathan Martin; Peterson, Gregory; Baby, Kavya; THOMAS, Jackson.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 43, No. 1, 02.2018, p. 150-153.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Impetigo: A need for new therapies in a world of increasing antimicrobial resistance

AU - D'CUNHA, Nathan Martin

AU - Peterson, Gregory

AU - Baby, Kavya

AU - THOMAS, Jackson

PY - 2018/2

Y1 - 2018/2

N2 - What is known and objective: Impetigo is a highly contagious bacterial skin infection and is one of the most common skin infections in children. Antibiotics are the first-line treatment when multiple lesions exist, but with an increasing prevalence of antibiotic-resistant bacteria the successful management of impetigo in the future is an area of concern.Comment: Current treatment options that favour the use of oral antibiotic therapy are increasingly problematic. Widespread use of these agents contributes to antimicrobial resistance and has adverse consequences for individuals and communities. There is a need for new topical antimicrobials and antiseptics as an alternative treatment strategy.What is new and conclusion: To successfully treat impetigo into the future and ensure that therapy does not contribute to bacterial resistance, additional research is required to ascertain the usefulness of alternative agents, including new topical antimicrobials and antiseptics.

AB - What is known and objective: Impetigo is a highly contagious bacterial skin infection and is one of the most common skin infections in children. Antibiotics are the first-line treatment when multiple lesions exist, but with an increasing prevalence of antibiotic-resistant bacteria the successful management of impetigo in the future is an area of concern.Comment: Current treatment options that favour the use of oral antibiotic therapy are increasingly problematic. Widespread use of these agents contributes to antimicrobial resistance and has adverse consequences for individuals and communities. There is a need for new topical antimicrobials and antiseptics as an alternative treatment strategy.What is new and conclusion: To successfully treat impetigo into the future and ensure that therapy does not contribute to bacterial resistance, additional research is required to ascertain the usefulness of alternative agents, including new topical antimicrobials and antiseptics.

KW - antibiotics

KW - antimicrobials

KW - bacterial resistance

KW - efficacy

KW - fusidic acid

KW - impetigo

KW - mupirocin

UR - http://www.scopus.com/inward/record.url?scp=85040017292&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/impetigo-need-new-therapies-world-increasing-antimicrobial-resistance

U2 - 10.1111/jcpt.12639

DO - 10.1111/jcpt.12639

M3 - Comment/debate

VL - 43

SP - 150

EP - 153

JO - Journal of Clinical and Hospital Pharmacy

JF - Journal of Clinical and Hospital Pharmacy

SN - 0269-4727

IS - 1

ER -